Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 129

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 129
---
 against, and any potential adverse outcome resulting from any such
proceeding) can be expensive, time-consuming, damage our reputation, and divert our management’s attention from other business concerns, which could seriously harm our business.

81

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this prospectus, including statements regarding our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, or intentions relating to product candidates and markets and business trends are forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “shall,” “should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions. These statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

| • |     | the initiation, timing, progress, potential registrational quality, and results of our research and development         
 programs, preclinical studies, any clinical trials, Investigational New Drug, or IND, and other regulatory submissions; |

| • |     | the ability of our approach to reproducibly predict treatment outcomes for  
 LB-102 amongst identified patient populations and achieve clinical success; |

| • |     | the timing of and costs involved in obtaining and maintaining regulatory approval of LB-102 and any future product candidates that we may identify or develop; |

| • |     | the beneficial characteristics, including potential safety, efficacy, and therapeutic effects, of LB-102; |

| • |     | our ability to efficiently and cost-effectively conduct our current and future clinical trials; |

| • |     | our ability to obtain funding for our operations necessary to complete further development and commercialization 
 of LB-102, if approved;                                                                                          |

| • |     | our ability to maintain existing,